RxDoctor Payments DataLook up a doctor →

Donnell Hammons, APRN

Nurse Practitioner · Norman, OKNPI 1548221005

Payments from drug & device makers

$9,075in general payments, 2019–2025

Across 478 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$900
  • AstraZeneca$814
  • AbbVie$732
  • Novo Nordisk$688
  • Astellas Pharma US Inc$636
  • GSK$622
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$9,01399%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,075 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Medicare billing

Part B allowed, 2024
$61,970
Medicare patients
150
Services billed
927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$48,514
OzempicSemaglutide29$34,807
JardianceEmpagliflozin23$17,297
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,377
Levothyroxine Sodium134$1,475
Albuterol Sulfate HfaAlbuterol Sulfate55$1,412
Gabapentin95$1,395
Omeprazole80$1,185
SynthroidLevothyroxine Sodium12$1,167
Losartan Potassium85$1,079
Duloxetine Hcl27$939
Escitalopram Oxalate57$889
Rosuvastatin Calcium57$766
Meloxicam56$689
Trazodone Hcl52$612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$900$48,51449 claims
Novo NordiskOzempic$688$34,80729 claims
Boehringer IngelheimJardiance$374$17,29723 claims
GSKAnoro Ellipta$622$5,37711 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$31$1,475134 claims
AbbVieSynthroid$732$1,16712 claims
Almatica Pharma LLCSertraline Hcl$28$32839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →